Verhistine

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Verhistine

Property Description
Active Ingredient Betahistine
Form Tablet (Oral Formulation)
Pharmacological Class Anti-vertigo Agent, Histamine Analogue
General Purpose Managing symptoms of vestibular disorders
Origin Synthetic Substance

Verhistine is a synthetic pharmaceutical preparation containing the active ingredient Betahistine, classified primarily as a specialized anti-vertigo agent. It is designated as a prescription-only medicine (Rx), intended for the systemic support of symptoms related to inner ear disorders. The drug entity is a small molecule drug that operates through its specific influence on the body's histamine system.


What Type of Medicine is Verhistine (Betahistine)?

Verhistine belongs to the pharmacological class of histamine analogues, meaning its chemical structure is similar to the naturally occurring substance histamine. The substance is included in the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system as a preparation specifically used for vertigo. The core of the preparation is Betahistine, which functions with a unique dual action: a potent Histamine H3-receptor antagonist and a weak Histamine H1-receptor agonist. This provides a targeted neuropharmacological effect intended for the chronic management of vestibular disorders.


Verhistine Composition and Form

The core of the preparation is Betahistine, most commonly utilized as the stable salt Betahistine dihydrochloride. The drug is consistently delivered as an oral formulation, typically a compressed tablet, which is the standardized dosage form for its intended oral route of administration. This single active ingredient product is well-suited for long-term management. The tablets consist of the active substance plus necessary solid excipients required to ensure manufacturing stability.


What is the General Purpose of Taking Verhistine?

The general purpose of Verhistine is to help the body address the underlying physiological disturbances associated with inner ear conditions that manifest as intense dizziness and loss of stability. Betahistine achieves this by helping to enhance microcirculation within the cochlea and vestibular structures and by modulating inner ear balance signals. The modulation of blood flow to the inner ear is a mechanism utilized in the management of these specialized conditions. This action supports the patient by relieving the frequency and intensity of symptomatic vertigo episodes, aiming to restore functional stability.

Regulatory References

  1. NIH/NLM (National Library of Medicine) Betahistine review

What side effects are possible with Verhistine?

Possible Side Effects and Safety Information

The safety profile of Verhistine (Betahistine) is based on clinical trial data and post-marketing surveillance as documented in official government regulatory texts. Adverse reactions are classified according to frequency and organized by the physiological systems affected, consistent with regulatory reporting standards.


Officially Documented Adverse Reactions

The following effects are listed in official documents and grouped by system-organ class:

System-Organ Class Frequency Classification Adverse Reaction
Gastrointestinal Disorders Common Nausea, Dyspepsia (Indigestion)
Nervous System Disorders Common Headache
Immune System Disorders Not Known Hypersensitivity Reactions (including anaphylaxis)
Skin and Subcutaneous Tissue Disorders Not Known Rash, Pruritus (itching), Urticaria (hives)

Common reactions are expected to occur in more than 1 in 100 but less than 1 in 10 patients. Reactions classified as Not Known have been identified through post-marketing surveillance but their exact frequency cannot be reliably estimated from available data.


Specific Safety Considerations

Official regulatory information emphasizes that the medicine requires particular caution in patients with specific pre-existing conditions. These safety constraints are due to Betahistine's effects as a histamine analogue:

  • Bronchial Asthma
  • Peptic Ulcer (or a history of the condition)
  • Phaeochromocytoma

Furthermore, regulatory notes specify that gastrointestinal disturbances—a common side effect—may be reduced by taking the tablet with food or during a meal.

Overdose and Emergency Response

Overdose and when to seek help

Verhistine is a substance commonly identified in scientific literature and international regulatory summaries as the active ingredient betahistine. Information regarding overdose is derived from published case reports and post-marketing surveillance data, which informs the patient-facing guidance.

Overdose Manifestations and Immediate Action

Symptoms of an overdose may include nausea, somnolence (sleepiness), and abdominal pain. These are generally reported with ingestion of high doses, such as those around 640 mg, which are considered mild to moderate in severity.

More serious complications—such as convulsions, cardiac complications, or pulmonary complications—have been observed in cases involving intentional massive overdose, particularly when Verhistine was taken in combination with other pharmaceutical agents.

Urgent medical attention is required if any signs of overdose are suspected or if a dose significantly higher than the prescribed amount has been taken. Since there is no specific antidote, treatment consists of standard supportive measures, which must be administered by healthcare professionals.

Overdose Context

  • Factors Associated with Severe Overdose: Intentional high-dose ingestion and co-ingestion with other drugs (polypharmacy).
  • Population Note: No specific population-based risk factors for severe overdose are routinely highlighted beyond the general risk of drug-drug interactions.

If you suspect an overdose, contact emergency services immediately.

Therapeutic Uses of Verhistine

What Verhistine treats: main uses and benefits

Verhistine (Betahistine) is commonly used to help with symptoms of Ménière's disease and is considered relevant for inner ear conditions where functional stability becomes affected. It is applied across domains where additional symptomatic support is needed in contexts involving heightened systemic burden.

The medication is generally used to help with the severity and frequency of recurrent vertigo episodes, which may assist patients with coping more steadily with symptom fluctuations. This treatment is relevant for easing symptoms that interfere with daily comfort, such as the spinning sensation, ringing in the ears (tinnitus), and the subjective feeling of aural fullness. The goal of symptomatic relief is to address the frequent dizziness.

By addressing the core symptoms associated with inner ear conditions, the treatment may assist with stability when symptoms interfere with daily functioning. This provides supportive relief when symptoms become more noticeable, helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Vestibular Symptoms

Verhistine is generally used to help with symptoms associated with vestibular disorders that cause acute or disruptive episodes of intense dizziness and imbalance. It supports the patient by contributing to easing the overall symptom load.

Eligibility and Restrictions for Use

Official Eligibility Status

The use of Verhistine (Betahistine) is determined by specific rules established in government regulatory documents. The medication is primarily intended for use in adults and requires close adherence to the official eligibility criteria.

Population Status Regulatory Rule
Absolutely Contraindicated Phaeochromocytoma and confirmed Hypersensitivity to the drug or its excipients are absolute prohibitions. Use is also contraindicated in patients with an active or historical Peptic Ulcer in some regions.
Use Not Recommended Children and adolescents under 18 years are not recommended to use Verhistine due to insufficient regulatory data on safety and efficacy in this age group.
Pregnancy/Lactation Use during pregnancy and lactation is generally not recommended due to a lack of adequate human safety data, requiring a clinical decision only when potential benefit is clearly established.

Cautionary Use

The product label advises caution in certain clinical conditions, including patients with bronchial asthma or severe hypotension. For older adults and those with hepatic or renal impairment, no specific dose adjustment is typically considered necessary based on post-marketing experience.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation requires the reporting of several categories of interactions for Verhistine, focusing on co-administered medicinal products that alter its exposure or its therapeutic effect.

Interaction Classification Interacting Product Category
Therapeutic Efficacy Decrease Antihistamines (H1 antagonists)
Increased Exposure Risk Monoamine Oxidase (MAO) Inhibitors

Co-administration with Antihistamines (H1 antagonists) is officially noted as having the potential to result in a mutual attenuation of effect between the agents, as they may act competitively. This implies a constrained use where the benefit of Verhistine may be reduced. Specific examples of agents in this class that may decrease efficacy include Cetirizine and Chlorpheniramine-related compounds.

Interactions that affect the systemic concentration of Verhistine are also documented. Regulatory data indicate that the metabolism of Verhistine may be inhibited by drugs that block Monoamine Oxidase (MAO) enzymes. This pharmacokinetic interaction may lead to an increase in Verhistine's exposure in the bloodstream, necessitating caution during concurrent use. This is classified as an Exposure Constraint, which may require monitoring or a change to the dose of Verhistine to manage the increased circulating levels.

Mechanism of Action

Verhistine, which is betahistine, primarily modulates the histaminergic system by acting as a weak partial agonist at the Histamine H1 receptors ( H1 R) and a more prominent antagonist at the Histamine H3 receptors ( H3 R). The H1 R agonism stimulates these receptors, particularly on the microvasculature of the inner ear, triggering localized vasodilation and enhancing vascular permeability. This vascular action results in increased microcirculation and blood flow to the cochlea and vestibular labyrinth.

Simultaneously, the H3 R antagonism targets these presynaptic autoreceptors located on histaminergic neurons, notably in the tuberomammillary nuclei and vestibular nuclei of the central nervous system. Blocking the inhibitory H3 R elevates the synthesis and release of endogenous histamine and other neurotransmitters (e.g., acetylcholine, norepinephrine) into the synaptic cleft. This augmented central histaminergic activity facilitates the neuronal plasticity required for vestibular compensation, modulating the asymmetrical neuronal firing rate between the vestibular nuclei. The peripheral vascular and central neuromodulatory effects collectively influence the dynamics of endolymphatic fluid pressure within the inner ear structures.

Dosage and Administration Information

How to Use Verhistine: Official Administration Guidelines

Verhistine (Betahistine) is a prescription-only medication administered exclusively by the oral route using a tablet formulation. The usage pattern is defined for long-term supportive management, not for immediate, acute relief.


Labeled Dosing and Administration

The treatment protocol for adults specifies an initial daily dose ranging from 24 mg up to a maximum of 48 mg daily. The total daily dose is divided into two or three separate doses to be taken throughout the day. Dosage adjustment is individually determined by a healthcare provider based on the patient's long-term response.

Tablets should be swallowed whole with water. A key instruction is to take the medication preferably with or immediately following a meal. This administration method is utilized to mitigate the potential for mild gastrointestinal discomfort, without affecting the absorption profile.


Population-Specific Use

Verhistine is intended for the adult population. For the pediatric population (under 18 years), the use of Verhistine is not recommended due to insufficient data regarding its use in this age group. For older adults and patients with known hepatic or renal impairment, no dose adjustment is generally indicated.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Verhistine

Evidence for Use in Ménière's Disease and Syndrome

Research examined Verhistine (Betahistine) in the context of conditions characterized by fluctuating or episodic manifestations, particularly Ménière's disease. Studies conducted for this purpose include Randomized Controlled Trials (RCTs) and reviews that summarize evidence from multiple studies. These trials were designed to measure outcomes describing episodic or acute changes, such as the number and intensity of vertigo attacks, and patient-reported outcomes describing discomfort related to tinnitus.

The evidence gathered for this indication contributes to understanding symptom patterns, but findings were mixed when combined in high-level reviews. Some trials monitored outcomes related to vertigo episodes, while others reported no measurable difference compared to placebo. Overall, the research highlights changes measured during the study period, but certainty remains low based on systematic reviews of the evidence for Ménière's disease.

Evidence for Use in Vestibular Vertigo

Research also studied Verhistine for more general peripheral vestibular vertigo, which are conditions where symptoms may vary in intensity. This evidence includes RCTs and large observational studies (real-world evidence) focusing on routine patient care. These studies primarily examined outcomes related to systemic or functional imbalance, such as the severity and frequency of dizziness.

Reports from observational studies described the evolution of symptom scores and tracked quality of life measurements over a defined study period. Evidence also contributed to understanding patient-reported outcomes describing perceived discomfort related to overall symptom load. However, the existing evidence for general vestibular vertigo is characterized by heterogeneity, and comparative evidence against other treatments is lacking.

What is Still Uncertain About the Research for Verhistine

The evidence landscape highlights several key limitations. Evidence quality varies across studies, leading to mixed findings in systematic reviews. Furthermore, the studies relied on patient-reported outcomes describing perceived discomfort, meaning that subjective elements were central to how symptoms were measured. Long-term effects are not fully established, and follow-up durations were limited in many of the higher-quality trials. Research does not determine whether an individual will respond similarly to the patterns observed in the group studies.

Frequently Asked Questions (FAQ)

Common questions about Verhistine (FAQ)


Q: How quickly should I expect Verhistine to start working?

A: Verhistine is intended for long-term supportive management, not for immediate relief. Official guidance states that an improvement in symptoms may sometimes only be observed after a couple of weeks of consistent treatment. Optimal benefit is generally observed after continued use, sometimes over several months.

Q: What's the typical duration of effect for a dose of Verhistine?

A: The active substance in Verhistine is quickly processed by the body, with its main components having a short half-life of only a few hours. Because of this, the total daily dose is typically divided into two or three separate doses to be taken throughout the day. Splitting the daily dose aims to sustain the presence of the medication to support symptom management.

Q: Is Verhistine considered a drowsy or non-drowsy medication?

A: Verhistine is generally not expected to cause sedation. Clinical studies have shown no or negligible effects on a person's ability to operate machinery. However, drowsiness has been reported in post-marketing surveillance with a 'Not Known' frequency. Patients are advised to monitor their own response to the medication.

Q: Will Verhistine interfere with my ability to drive or operate machinery?

A: The medicine itself is generally not likely to affect the ability to drive. However, the disease being treated, such as vertigo or Ménière's syndrome, can cause symptoms like dizziness or sickness. If experiencing dizziness or sickness, patients are advised to refrain from activities requiring full attention.

Q: What is the risk of Verhistine interacting with alcohol?

A: Official patient information indicates that caution is necessary regarding alcohol consumption while taking Verhistine. Drinking alcohol may potentially worsen the symptoms of dizziness or tiredness that are associated with both the medicine and the underlying condition.

Q: Can Verhistine be taken long-term or is it only for short-term use?

A: Verhistine is typically prescribed for long-term use as a supportive treatment for chronic inner ear conditions. Non-clinical data examining long-term use indicated general tolerability over the study periods.

Q: Do I need a prescription to buy Verhistine?

A: Yes, Verhistine (Betahistine) is officially classified as a prescription-only medicine (POM) in most countries. It can only be dispensed after a healthcare provider has issued a valid prescription.

Q: Is there a generic version of Verhistine available?

A: Yes, the active ingredient in Verhistine is Betahistine. This substance is commonly available globally under its generic name as well as many other brand names, depending on the country and manufacturer.

Q: What happens if I accidentally miss a dose of Verhistine?

A: If a dose is missed, it is generally advised that the dose is skipped entirely. The next dose should then be taken at the next regularly scheduled time. It is important that a double dose is not taken to compensate for a missed dose.

Q: Is it normal to feel dizzy the first few times I take Verhistine?

A: While the most common side effects are headache and stomach upset, some individuals may experience dizziness or feeling faint when they first start taking the medication. Patients should follow up with their healthcare provider if these symptoms persist or worsen.

Q: Are there any vitamins or supplements that interact with Verhistine?

A: Regulatory information indicates there is insufficient data regarding potential interactions with complementary medicines, herbal remedies, and nutritional supplements. Due to this lack of official data, consultation with a healthcare provider is recommended before combining them.

Q: What's the mechanism: How does Verhistine actually work in the body?

A: Verhistine is thought to work by influencing the body’s natural histamine system. This action is believed to increase blood flow to the microvessels of the inner ear. The medicine also affects the brain's balance centers to facilitate vestibular compensation, which helps the brain adjust to inner ear signal imbalances.

Q: What are some less common but serious side effects of Verhistine I should know about?

A: Official documents indicate that serious side effects are rare but include signs of a severe allergic reaction (hypersensitivity). This can involve anaphylaxis or severe skin reactions like hives (urticaria). Symptoms such as swelling of the face, tongue, or throat are indicators that require immediate clinical assessment.

Q: Can Verhistine affect my blood pressure?

A: The official product information advises caution when the medicine is used in people with severe hypotension (low blood pressure). The medicine is also strictly contraindicated (should not be used) in patients with Phaeochromocytoma, a rare condition that affects blood pressure regulation.

Q: Is Verhistine helpful for treating hives (urticaria)?

A: No, Verhistine is for managing inner ear conditions, not for treating hives. In fact, hives (urticaria) is listed in regulatory documents as a rare allergic side effect of the drug itself. Official information advises caution for patients with a history of hives (urticaria).

Q: Are there different strengths of Verhistine available?

A: Yes, to allow for individualized daily dosing based on a patient's response, the tablets are commonly available in multiple standard strengths. These typically include 8 mg, 16 mg, and 24 mg tablets.

Q: What does the latest research evidence say about Verhistine's effectiveness?

A: While widely prescribed, systematic reviews of the evidence for certain conditions like Ménière's disease state that there is insufficient evidence to definitively indicate whether the drug has a measurable effect compared to placebo. The research is ongoing and varied across study types.

Q: Is Verhistine known to interact with common pain relievers like ibuprofen?

A: Official regulatory sources report no known hazardous interactions with common, non-prescription pain relievers such as ibuprofen or paracetamol. The primary drug-to-drug interactions to be cautious of are with Antihistamines and MAO Inhibitors.

Q: Can Verhistine be used to help with itchy skin?

A: No, Verhistine is not prescribed for itchy skin; its function is to manage inner ear symptoms. Conversely, pruritus (itchy skin) is listed in official sources as a possible but rare allergic reaction to the medicine itself.

Q: What's the difference between Verhistine tablets and the liquid form?

A: Regulatory and official product information for Verhistine consistently describes it as an oral tablet formulation. An official liquid or alternative dosage form is not typically described in the standard prescribing information.

Q: Is Verhistine a relatively new drug or has it been around for a while?

A: The active ingredient, Betahistine, has been in clinical use for an extended period in many countries globally. It was first introduced and registered in Europe in the 1970s and has a long history of use.

Q: Are the side effects of Verhistine generally mild?

A: The most frequently reported side effects, which include nausea, indigestion, and headache, are classified as 'Common' (1–10 in 100 people) and are typically considered mild. Taking the tablets with food is recommended to help minimize gastrointestinal side effects.

Q: Do I need to adjust my diet while taking Verhistine?

A: Generally, patients can eat and drink normally while taking Verhistine. However, dietary considerations, such as a low-salt regimen, are sometimes recommended by clinicians as part of the overall management strategy for the underlying condition.

Q: Is it true that Verhistine might interact with certain antidepressants?

A: Yes, official regulatory documents advise caution when Verhistine is taken at the same time as Monoamine Oxidase (MAO) Inhibitors. These are a specific class of drugs sometimes used to treat depression and Parkinson's disease, as co-administration can increase the amount of Verhistine in the bloodstream.

Q: What is the purpose of the 'other ingredients' listed in Verhistine tablets?

A: The tablets contain the active ingredient plus a list of excipients, which are inactive 'other ingredients.' The purpose of these substances is to ensure the tablet has the necessary stability, correct structure, and proper dissolution rate when taken, making it suitable for manufacturing.

Q: Does taking Verhistine at night versus the morning make a difference?

A: The key instruction is that the total daily dose is split and taken in multiple administrations (two or three) throughout the day. The official guidance emphasizes taking the medication with or immediately following a meal to help reduce the possibility of stomach upset, rather than focusing on a specific time of day.

Q: What is the typical shelf-life or expiration of Verhistine?

A: When stored in its original packaging according to instructions, the official shelf life of Verhistine tablets is typically 3 years. The exact expiration date will always be printed clearly on the product packaging.

Q: Can Verhistine affect my sleep quality?

A: Post-marketing surveillance data has reported that some patients experience changes in sleep patterns. Both difficulty sleeping (insomnia) and somnolence (sleepiness) have been reported as undesirable effects, though their frequency is not precisely known.

How should Verhistine be stored and disposed of?

How to Store and Dispose of Verhistine?

The storage and disposal of Verhistine (Betahistine) must strictly follow the official instructions provided by regulatory authorities to ensure product stability and safety.

Storage Requirements

Verhistine tablets must be stored at controlled room temperature, which is typically maintained between 20 C and 25 C. The product requires protection from both light and moisture and must be kept in its original container until use. It is explicitly required to keep Verhistine out of the sight and reach of children.

Condition Requirement
Temperature Store below 25 C (Do not freeze)
Environment Protect from light and moisture
Access Keep out of reach of children

Disposal Instructions

Unused or expired Verhistine must be disposed of according to local regulations for medicinal products. The official labeling states that the medicine must not be discarded via wastewater or regular household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Verhistine found in:

A-Z Index: